Education
About Us
Working with TipRanks
Follow Us
Sartorius Stedim Biotech (GB:0RG8)
LSE:0RG8
0RG8 Stock Chart & Stats
€167.10
-€0.39(-0.20%)
At close: 4:00 PM EST
€167.10
-€0.39(-0.20%)
Day’s Range― - ―
52-Week Range€149.70 - €223.20
Previous CloseN/A
Volume2.47K
Average Volume (3M)57.59K
Market Cap
€16.00B
Enterprise Value€18.32B
Total Cash (Recent Filing)€426.10M
Total Debt (Recent Filing)€2.75B
Price to Earnings (P/E)76.9
Beta1.52
Next Earnings
Apr 23, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.12
Shares Outstanding97,330,410
10 Day Avg. Volume38,577
30 Day Avg. Volume57,592
Financial Highlights & Ratios
PEG Ratio1.51
Price to Book (P/B)5.00
Price to Sales (P/S)6.89
P/FCF Ratio140.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€237.43Price Target Upside42.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)5.16
Revenue Forecast (FY)€3.18B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueSartorius Stedim's business model includes a durable annuity-like stream from single-use consumables that customers must replenish each batch. This recurring demand increases revenue visibility, customer stickiness and margin stability over the medium term as manufacturers scale biologics production.
Strong TTM Revenue ReboundA sharp TTM revenue rebound with improving profitability signals recovering end-market demand and product uptake, which supports sustainable top-line momentum. Sustained revenue growth improves operating leverage and funds reinvestment into R&D, service and capacity over the next several quarters.
Improved Leverage RatioThe material improvement in leverage enhances financial flexibility and lowers solvency risk, enabling the company to better absorb cyclical swings and invest in capex or M&A. A healthier ratio reduces refinancing pressure and supports multi‑quarter stability in capital structure management.
Bears Say
Weak Free Cash Flow ConversionSubstantial decline in free cash flow and poor conversion of earnings into cash signal operating or working‑capital inefficiencies. Lower FCF constrains self‑funding of growth, increases reliance on external financing, and limits capacity to sustainably increase dividends or accelerate strategic investments.
Margins Well Below Prior PeakNet margins compressed significantly versus the prior peak, indicating structural pressures on pricing, product mix or cost base. Even with revenue recovery, incomplete margin restoration reduces long‑term earnings power and return on capital, leaving profitability vulnerable across the medium term.
High Absolute Debt StockA large absolute debt burden increases fixed interest and principal obligations, limiting financial optionality. Coupled with weakened free cash flow, the high nominal debt elevates refinancing, interest‑rate and covenant risks and can constrain strategic spending over the coming quarters.
Sartorius Stedim Biotech News
0RG8 FAQ
What was Sartorius Stedim Biotech’s price range in the past 12 months?
Sartorius Stedim Biotech lowest share price was €149.70 and its highest was €223.20 in the past 12 months.
What is Sartorius Stedim Biotech’s market cap?
Sartorius Stedim Biotech’s market cap is €16.00B.
When is Sartorius Stedim Biotech’s upcoming earnings report date?
Sartorius Stedim Biotech’s upcoming earnings report date is Apr 23, 2026 which is in 32 days.
How were Sartorius Stedim Biotech’s earnings last quarter?
Sartorius Stedim Biotech released its earnings results on Feb 03, 2026. The company reported €1.12 earnings per share for the quarter, missing the consensus estimate of €1.264 by -€0.144.
Is Sartorius Stedim Biotech overvalued?
According to Wall Street analysts Sartorius Stedim Biotech’s price is currently Undervalued.
Does Sartorius Stedim Biotech pay dividends?
Sartorius Stedim Biotech does not currently pay dividends.
What is Sartorius Stedim Biotech’s EPS estimate?
Sartorius Stedim Biotech’s EPS estimate is 1.23.
How many shares outstanding does Sartorius Stedim Biotech have?
Sartorius Stedim Biotech has 97,330,410 shares outstanding.
What happened to Sartorius Stedim Biotech’s price movement after its last earnings report?
Sartorius Stedim Biotech reported an EPS of €1.12 in its last earnings report, missing expectations of €1.264. Following the earnings report the stock price went up 3.365%.
Which hedge fund is a major shareholder of Sartorius Stedim Biotech?
Currently, no hedge funds are holding shares in GB:0RG8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sartorius Stedim Biotech
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
0RG8 Stock 12 Month Forecast
Average Price Target
€237.43
▲(42.09% Upside)
Technical Analysis
Options Prices
Currently, No data available
---